

25 February 2022

## Botanix to present at ShareCafe Small Cap "Hidden Gems" Webinar

**Philadelphia PA and Perth Australia, 25 February 2022:** Clinical dermatology company, Botanix Pharmaceuticals Limited (ASX: BOT, "Botanix" or "the Company"), is pleased to announce its participation in the ShareCafe Small Cap "Hidden Gems" Webinar, being held today, Friday 25<sup>th</sup> of February 2022.

The webinar will open with Botanix's presentation at 9:30am AWST (Perth) / 12:30pm AEDT (Sydney/Melbourne) with Executive Director, Matt Callahan providing an overview of its clinical pipeline, the significant potential for novel products in the dermatology sector and opportunities for adding new assets to the Botanix pipeline, as well as the upcoming clinical and operational milestones for 2022.

To view Botanix's presentation, please register [here](#).

A copy of the investor presentation to be delivered during the webinar is attached.

Release authorised by

**Vince Ippolito**

President and Executive Chairman

### About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX: BOT) is a dermatology focused company based in Perth (Australia) and Philadelphia (USA) committed to the development of pharmaceutical products that are underpinned by science and supported by well-controlled randomised clinical trials. The Company has two separate development platforms - dermatology and antimicrobial products - both of which currently leverage the unique anti-inflammatory, immune modulating and antimicrobial properties of cannabinoids, particularly synthetic cannabidiol or CBD. Botanix has an exclusive license to use a proprietary drug delivery system (Permetrex™) for direct skin delivery of active pharmaceuticals in all skin diseases, which it utilises in its existing development programs and is being explored with a view to being utilized in a number of other product opportunities. To learn more please visit: <http://www.botanixpharma.com/>

**For more information, please contact:**

#### General enquiries

Corporate Communications

Botanix Pharmaceuticals

P: +61 8 6555 2945

[investors@botanixpharma.com](mailto:investors@botanixpharma.com)

#### Investor enquiries

Hannah Howlett

WE Communications

P: +61 450 648 064

[hhowlett@we-worldwide.com](mailto:hhowlett@we-worldwide.com)

#### Media enquiries

Haley Chartres

H^CK

P: +61 423 139 163

[haley@hck.digital](mailto:haley@hck.digital)

For personal use only

### Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

For personal use only

Personal use only  
Advancing new treatments for skin disease and infection



# Investor Presentation

February 2022

# Botanix Pharmaceuticals: a clinical stage dermatology company

Targeting billion-dollar markets with novel products



## Pharmaceutical focus

Developing novel treatments for common skin diseases (such as rosacea and acne), as well as life threatening bacterial infections



## Topically driven

Dermatologists prefer creams and gels as first line treatment and our novel skin delivery technology (Permetrex™), provides a cosmetically elegant solution



## Significant markets

Pipeline targets multi-billion dollar markets, with no new 'mechanism of action' products approved by FDA in decades for target indications in acne and rosacea



## World-class team


World-class and experienced team, with significant dermatology and antimicrobial drug track records as well as exits




## Near-term catalysts

Multiple upcoming catalysts including completion of Phase 1b/2 rosacea study, commencement Phase 2 antimicrobial study, canine AD data readout and new pipeline opportunities

# Advanced late-stage pipeline



# Target markets with significant annual revenues & unmet needs



1. Grandview Research. [www.Grandview\\_research.com](http://www.Grandview_research.com)  
 2. Using GSK Bactroban Nasal Pricing/BTX 1801 pricing to be developed following analyses of potential impact on healthcare system; assumes 5% YOY pricing following product approval/launch  
 3. Symphony Health Solutions, METYS, data ending December 2019 – weighted

Personal use only

# Synthetic cannabinoids are well suited to treat skin diseases and infections

Botanix's studies show synthetic CBD to:<sup>1</sup>

- ✓ Be safe and well tolerated
- ✓ Have broad anti-inflammatory properties
- ✓ Have a strong and consistent impact on skin lesions
- ✓ Have anti-microbial properties – kills *Staph aureus*<sup>2</sup>
- ✓ Have potential for widespread use across human and animal health
- ✓ Have anti-inflammatory and anti-microbial properties important for dermatology conditions including acne, rosacea and dermatitis

1. See ASX announcement “Antimicrobial Platform Update and Launch of BTX 1801 Study” (13 March 2020) and The Antimicrobial Potential of Cannabidiol, Communications Biology 4, Article number: 7 (2021) Blaskovich, M et al
2. Staphylococcus aureus (S. Aureus) is a common bacterium that lives on skin & nasal passages.. It can cause skin infection & serious or life-threatening infection.

# BTX 1702: high impact of rosacea on patients and significant market opportunity

❖ Papulopustular rosacea is a highly visible **chronic skin disease** characterised by **redness (inflammation) and acne-like-break-outs<sup>1</sup>**

❖ Patients diagnosed with Rosacea tend to have higher incidences<sup>2</sup> of:

- Depression
- Social anxiety
- Embarrassment
- Decreased quality of life

## Phase 1b/2 Study design

❖ **Three dose groups, ~120 patients:**

- BTX 1702 high dose, BTX 1702 low dose and vehicle (placebo)

❖ **Sites:** ~15 dermatology sites across Australia and NZ

❖ **Patients:** adults with moderate to severe papulopustular rosacea

❖ **Treatment period:** 8 weeks

❖ **Timing:** full enrolment mid 2022



# BTX 1801: targeting blood stream infections in haemodialysis patients with central venous catheters



## Rationale for selection

- ❖ Infection is a leading cause of death with 20% to 40% of haemodialysis patients eventually dying from an infection<sup>1</sup>



## Significant health risks

- ❖ Risks for central venous catheter-related complications were as high as 30% and 38%, at 1 and 2 years respectively<sup>2</sup>
- ❖ Central venous catheter patients (approx. 160,000) make up more than 70% of blood infections in the dialysis population<sup>2</sup>



Phase  
2a data



## Safety & tolerability

- ✓ Safe and generally well tolerated at doses of up to 20%
- ✓ All 66 participants successfully completed the BTX 1801 study
- ✓ No severe adverse events reported<sup>1</sup>



## Efficacy

- ✓ Efficacy demonstrated for primary endpoint at Day 12
- ✓ Eradication rates as high as 76.2% at Day 7, with eradication extending through to Day 28, despite no treatment after Day 5

# Executing on key clinical milestones

## ❖ **Antimicrobial: BTX 1801 Phase 2b study**

*Positive Phase 2a results announced, Phase 2b study start end 1Q 2022*

## ❖ **Rosacea: BTX 1702 Phase 1b/2 study**

*Targeting full enrolment mid 2022, with data 3Q 2022*

## ❖ **Acne: BTX 1503 for Phase 3 clinical studies**

*Pending completion of BTX 1702 Phase 1b/2 study*

## ❖ **Dermatitis: BTX 1204A canine proof of concept study**

*Enrolment targeting completion end 1Q CY2022, data 2Q 2022*

## ❖ **Pipeline opportunities**

*Exploring other pipeline opportunities for later stage dermatology assets*



Dates are calendar years

# DISCLAIMER

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.